T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (833)	1/28/2002 1:50:47 PM
From: JMarcus	Read Replies (1) of 2243

<<What would we get for our buck apart from arestin>> The rest of the pipeline is early stage. From the 10Q: <<As of September 30, 2001, we have also completed preclinical trials on our new product candidate for bone regeneration, which focuses on dental implantation and orthopedics. On August 27, 2001 we announced the start of Phase 1 human clinical trials for our product that focuses on oral mucositis, a condition secondary to certain cancer treatments. We expect to begin Phase I human clinical trials for our bone regeneration product prior to year-end 2001.>> I've heard before (and the CEO certainly said) that mucositis is a big problem for many chemotherapy patients. Atridox may be superior, but calling it "far superior" seems like a stretch. Given the conservative bent of dentists (for heaven's sake, they are still using drills on people -- talk about medieval!), my bet is that speed and ease of use will carry more weight than marginally-more-effective. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next